Isabelle Mahé on Reduced Dose Apixaban for Cancer-Associated VTE: API-CAT Trial Results
Isabelle Mahé, Head of Internal Medicine, Louis Mourier Hospital, APHP, Paris Cité University, reposted from Syed Saad Mahmood on LinkedIn:
”Thank you very much for the opportunity to discuss the results of the API-CAT Study adressing the extended anticoagulant treatment in patients with cancer associated thrombosis!”
Syed Saad Mahmood, System Director, Cardio-Oncology at Catholic Health, shared on LinkedIn:
”*St Francis Heart Center, NY CardioOncology Journal Club*
Dr. Isabelle Mahe (Université Paris Cité, France) joined us to discuss *API-CAT trial* evaluating whether among active cancer patients with venous thromboembolism, tx with a reduced dose oral anticoagulant is effective in preventing recurrent thromboembolic events and reduced bleeding”
Find more from Cardio-Oncology Journal Club.
Watch the full episode here.
Stay updated on the latest advancements in hemostasis research with Hemostasis Today.
-
Dec 20, 2025, 18:30Kate Scrivener on Cochrane Review: 2025 Ends With a Big Milestone!
-
Dec 20, 2025, 18:15Shekher Bose on AstraZeneca’s Voluntary Withdrawal of Andexxa
-
Dec 20, 2025, 17:10Mina Adel Nagi on the Future of ESR Testing with HORIBA’s CoRA Technology
-
Dec 20, 2025, 16:50Geert Verheyden on Advancing Stroke Rehabilitation Through Collaboration and Innovation
-
Dec 20, 2025, 16:26Dirk Sibbing on Antithrombotic Drugs for ACS in Women
-
Dec 20, 2025, 16:13Akshat Jain Explains VWF/FVIII Prophylaxis in Children Under 6
-
Dec 20, 2025, 15:49Manuel Requena Shares The Results of the RESISTANT International Registry
-
Dec 20, 2025, 13:49Harshal Kale: Wishing Our Community a Bright Start to 2026
-
Dec 20, 2025, 12:23Healthcare is a Human Right: Strengthening Blood Donation in Armenia